

**Pharmaceutical Industry Contributions**

Entities highlighted in green lobbied directly on pharmaceutical issues in Maryland during this period.

Receiving Committee	Contribution Date	Contributor Name	Contribution Amount
Hogan, Larry for Governor	11/17/16	Pfizer Inc.	\$3,000
Republican Governors Association	2/24/17	Sumitomo Dainippon Pharma Co.	\$75,000
Republican Governors Association	3/31/17	Pharmaceutical Research Managers of America	\$250,000
Republican Governors Association	3/31/17	Vertex Pharmaceuticals	\$100,000
Republican Governors Association	3/31/17	Novo Nordisk	\$50,000
Republican Governors Association	3/31/17	Novo Nordisk	\$50,000
Republican Governors Association	4/25/17	Sanofi US Services	\$250,000
Republican Governors Association	4/25/17	Abbvie	\$75,000
Republican Governors Association	4/25/17	Abbvie	\$25,000
Republican Governors Association	5/5/17	GlaxoSmithKline	\$50,000
Republican Governors Association	5/9/17	Novartis	\$100,000
Republican Governors Association	5/12/17	Fresenius Medical Care	\$50,000
Republican Governors Association	5/17/17	AstraZeneca	\$200,000
Republican Governors Association	6/15/17	Genentech	\$100,000
Republican Governors Association	6/27/17	Astellas Pharma	\$50,000
Hogan, Larry for Governor	7/25/17	Sanofi US Services Inc. Employee's PAC	\$1,500
Hogan, Larry for Governor	7/27/17	Astellas Pharma	\$1,500
Republican State Central Committee Of Maryland	7/31/17	PhRMA	\$3,000
Hogan, Larry for Governor	8/7/17	PhRMA	\$2,000
Hogan, Larry for Governor	8/7/17	Novartis	\$1,500
Hogan, Larry for Governor	8/22/17	Pfizer PAC	\$3,000
Hogan, Larry for Governor	9/28/17	GlaxoSmithKline	\$1,500

Hogan, Larry for Governor	12/13/17	Pfizer Inc.	\$3,000
Republican Governor's Association (MD IE)	5/15/18	Astellas Pharma	\$100,000
<b>Hogan for Governor TOTAL</b>			<b>\$17,000</b>
<b>RGA MD IE TOTAL</b>			<b>\$100,000</b>
<b>RGA TOTAL</b>			<b>\$1,425,000</b>
<b>MD GOP TOTAL</b>			<b>\$3,000</b>

*Lobbying Activity*

Company	Report	Period	Lobbying Area
Pfizer	<a href="#">Link</a>	11/1/16-10/31/17	HB 631
Mylan	<a href="#">Link</a>	11/1/16-10/31/17	"Legislative matters regarding drug prices"
Novartis	<a href="#">Link</a>	11/1/16-10/31/17	"Pharmaceuticals"
Sanofi	<a href="#">Link</a>	11/1/16-10/31/17	"Pharmaceuticals"
GlaxoSmithKline	<a href="#">Link</a>	11/1/16-10/31/17	"Pharmaceuticals"
Pharmaceutical Research & Manufacturers of America	<a href="#">Link</a>	11/1/16-10/31/17	HB 631
Pharmaceutical Research & Manufacturers of America	<a href="#">Link</a>	11/21/16-10/31/17	HB 631
Vertex	<a href="#">Link</a>	11/1/16-10/31/17	"Pharmaceuticals"
AstraZeneca	<a href="#">Link</a>	11/1/16-10/31/17	"Pharmaceuticals"